Avoro Capital Advisors LLC Trims Stock Position in Autolus Therapeutics plc (NASDAQ:AUTL)

Avoro Capital Advisors LLC decreased its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 19.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,910,642 shares of the company's stock after selling 2,435,036 shares during the period. Avoro Capital Advisors LLC owned about 3.72% of Autolus Therapeutics worth $23,290,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. State Street Corp grew its stake in shares of Autolus Therapeutics by 1.7% during the 3rd quarter. State Street Corp now owns 606,544 shares of the company's stock valued at $2,202,000 after purchasing an additional 10,401 shares during the period. JPMorgan Chase & Co. raised its position in Autolus Therapeutics by 145.3% in the third quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company's stock worth $4,663,000 after acquiring an additional 761,008 shares during the period. Hennion & Walsh Asset Management Inc. purchased a new position in shares of Autolus Therapeutics during the 4th quarter worth $611,000. Avanza Fonder AB bought a new stake in shares of Autolus Therapeutics during the 4th quarter valued at $75,000. Finally, Arkadios Wealth Advisors purchased a new stake in shares of Autolus Therapeutics in the 4th quarter worth $47,000. Hedge funds and other institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Price Performance

Shares of AUTL traded down $0.07 during mid-day trading on Friday, reaching $1.33. 2,740,804 shares of the company's stock traded hands, compared to its average volume of 1,479,020. The stock's 50-day moving average is $1.65 and its two-hundred day moving average is $2.49. Autolus Therapeutics plc has a 12 month low of $1.11 and a 12 month high of $5.00. The stock has a market cap of $353.91 million, a P/E ratio of -1.10 and a beta of 2.06.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.12. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $2.98 million. Research analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Truist Financial lowered their target price on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Wells Fargo & Company cut their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research note on Friday, March 21st. Finally, Needham & Company LLC restated a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a research note on Thursday, April 10th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Autolus Therapeutics presently has an average rating of "Buy" and a consensus price target of $9.32.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.